A detailed history of Charles Schwab Investment Management Inc transactions in Rx Sight, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 285,329 shares of RXST stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
285,329
Previous 222,822 28.05%
Holding current value
$12.8 Million
Previous $13.4 Million 5.19%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.78 - $57.04 $2.55 Million - $3.57 Million
62,507 Added 28.05%
285,329 $14.1 Million
Q2 2024

Aug 12, 2024

BUY
$50.42 - $64.29 $1.47 Million - $1.87 Million
29,078 Added 15.01%
222,822 $13.4 Million
Q1 2024

May 08, 2024

BUY
$35.51 - $57.92 $120,982 - $197,333
3,407 Added 1.79%
193,744 $9.99 Million
Q4 2023

Feb 06, 2024

BUY
$20.91 - $40.9 $167,342 - $327,322
8,003 Added 4.39%
190,337 $7.67 Million
Q3 2023

Nov 08, 2023

BUY
$27.05 - $33.37 $3.01 Million - $3.72 Million
111,403 Added 157.06%
182,334 $5.09 Million
Q2 2023

Aug 09, 2023

BUY
$16.37 - $28.9 $166,237 - $293,479
10,155 Added 16.71%
70,931 $2.04 Million
Q1 2023

May 11, 2023

BUY
$12.58 - $16.68 $93,897 - $124,499
7,464 Added 14.0%
60,776 $1.01 Million
Q4 2022

Feb 13, 2023

BUY
$9.93 - $14.2 $12,055 - $17,238
1,214 Added 2.33%
53,312 $675,000
Q3 2022

Nov 14, 2022

BUY
$11.19 - $15.85 $39,411 - $55,823
3,522 Added 7.25%
52,098 $626,000
Q2 2022

Aug 15, 2022

BUY
$10.61 - $16.66 $64,784 - $101,725
6,106 Added 14.38%
48,576 $684,000
Q1 2022

May 13, 2022

BUY
$8.97 - $14.03 $177,919 - $278,285
19,835 Added 87.63%
42,470 $526,000
Q4 2021

Feb 11, 2022

BUY
$9.52 - $13.81 $23,390 - $33,931
2,457 Added 12.18%
22,635 $255,000
Q3 2021

Nov 16, 2021

BUY
$11.85 - $17.32 $239,109 - $349,482
20,178 New
20,178 $256,000

Others Institutions Holding RXST

About RxSight, Inc.


  • Ticker RXST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 27,638,900
  • Market Cap $1.24B
  • Description
  • RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...
More about RXST
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.